Pharma Mar Future Growth
Future criteria checks 5/6
Pharma Mar is forecast to grow earnings and revenue by 46.4% and 17.8% per annum respectively. EPS is expected to grow by 1.4% per annum. Return on equity is forecast to be 33.7% in 3 years.
Key information
46.4%
Earnings growth rate
1.4%
EPS growth rate
Biotechs earnings growth | 33.8% |
Revenue growth rate | 17.8% |
Future return on equity | 33.7% |
Analyst coverage | Low |
Last updated | 22 Jul 2024 |
Recent future growth updates
Recent updates
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jul 28Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Jun 01Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
May 28Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 237 | 92 | 98 | 110 | 4 |
12/31/2025 | 198 | 59 | 63 | 73 | 4 |
12/31/2024 | 165 | 7 | 13 | 21 | 4 |
3/31/2024 | 162 | 2 | -35 | -12 | N/A |
12/31/2023 | 158 | 1 | -29 | -13 | N/A |
9/30/2023 | 168 | 14 | -29 | -13 | N/A |
6/30/2023 | 175 | 21 | -14 | -1 | N/A |
3/31/2023 | 177 | 29 | N/A | N/A | N/A |
12/31/2022 | 196 | 49 | 29 | 38 | N/A |
9/30/2022 | 235 | 79 | N/A | N/A | N/A |
6/30/2022 | 233 | 85 | 41 | 48 | N/A |
3/31/2022 | 232 | 91 | N/A | N/A | N/A |
12/31/2021 | 230 | 93 | 18 | 26 | N/A |
9/30/2021 | 188 | 63 | N/A | N/A | N/A |
6/30/2021 | 200 | 67 | 19 | 24 | N/A |
3/31/2021 | 222 | 91 | 113 | 117 | N/A |
12/31/2020 | 270 | 137 | 276 | 279 | N/A |
9/30/2020 | 246 | 147 | 264 | 270 | N/A |
6/30/2020 | 214 | 124 | 255 | 259 | N/A |
3/31/2020 | 166 | 72 | 161 | 165 | N/A |
12/31/2019 | 86 | -9 | -28 | -24 | N/A |
9/30/2019 | 136 | -27 | -24 | -23 | N/A |
6/30/2019 | 84 | -37 | -12 | -12 | N/A |
3/31/2019 | 154 | -24 | -24 | -22 | N/A |
12/31/2018 | 109 | -17 | -19 | -17 | N/A |
9/30/2018 | 189 | -16 | -23 | -20 | N/A |
6/30/2018 | 128 | -20 | -27 | -22 | N/A |
3/31/2018 | 179 | -26 | -24 | -19 | N/A |
12/31/2017 | 159 | -28 | N/A | -1 | N/A |
9/30/2017 | 182 | -22 | N/A | 4 | N/A |
6/30/2017 | 186 | -18 | N/A | 9 | N/A |
3/31/2017 | 184 | -19 | N/A | 13 | N/A |
12/31/2016 | 181 | -24 | N/A | -8 | N/A |
9/30/2016 | 187 | -18 | N/A | N/A | N/A |
6/30/2016 | 188 | -10 | N/A | 5 | N/A |
3/31/2016 | 190 | -7 | N/A | N/A | N/A |
12/31/2015 | 194 | 7 | N/A | 11 | N/A |
12/31/2014 | 175 | 13 | N/A | 23 | N/A |
12/31/2013 | 74 | 12 | N/A | 74 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHM's forecast earnings growth (46.4% per year) is above the savings rate (1.5%).
Earnings vs Market: PHM's earnings (46.4% per year) are forecast to grow faster than the Spanish market (9.3% per year).
High Growth Earnings: PHM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PHM's revenue (17.8% per year) is forecast to grow faster than the Spanish market (4.8% per year).
High Growth Revenue: PHM's revenue (17.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHM's Return on Equity is forecast to be high in 3 years time (33.7%)